» Articles » PMID: 15543611

Frequent Genetic and Biochemical Alterations of the PI 3-K/AKT/PTEN Pathway in Head and Neck Squamous Cell Carcinoma

Overview
Journal Int J Cancer
Specialty Oncology
Date 2004 Nov 16
PMID 15543611
Citations 98
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the status of the PI 3-kinase/AKT/PTEN signaling pathway in a series of 117 head and neck squamous cell carcinomas (HNSCC) in a search for molecular alterations in genes/proteins with potential prognostic value. For this purpose, PIK3CA and AKT2 gene amplification was assessed by multiplex and Quantitative Real-Time PCR. Protein expression of AKT, p-AKT, p110alpha and PTEN was determined by Western blot. PTEN allelic loss was evaluated by microsatellite analysis. PTEN-exon 5 was screened for point mutations by PCR-SSCP. Homozygous deletions were determined by multiplex PCR. PIK3CA gene was amplified in 43/117 (37%) fresh tumor samples, a frequency that did not differ from that found in archival premalignant tissues: 15/38 (39%); 12/40 (30%) fresh tumors harbored AKT2 gene amplification. AKT was found activated in 6/36 (17%) fresh tumor samples, when compared to their normal tissue counterparts. Of these 6 cases, 1 showed p110alpha overexpression and 5 displayed PTEN protein downregulation. Neither allelic loss (found in 11/77 informative cases) nor point mutations or homozygous deletions accounted for the reduced PTEN protein expression observed in our tumor series. The histologically normal mucosa of 4 patients displayed some of the molecular alterations analyzed. Dysregulation of the PI 3-K/AKT/PTEN pathway might contribute to early HNSCC tumorigenesis and might constitute a potential clinical target. Overall, 17/36 (47%) cases showed at least 1 of the molecular alterations studied here, which makes the PI 3-kinase-initiated signaling pathway one of the most frequently altered in HNSCC.

Citing Articles

Effect of Opioid Receptor Activation and Blockage on the Progression and Response to Treatment of Head and Neck Squamous Cell Carcinoma.

Levi L, Hikri E, Popovtzer A, Dayan A, Levi A, Bachar G J Clin Med. 2023; 12(4).

PMID: 36835812 PMC: 9967316. DOI: 10.3390/jcm12041277.


Influence of the Microbiome Metagenomics and Epigenomics on Gastric Cancer.

Mathebela P, Damane B, Mulaudzi T, Mkhize-Khwitshana Z, Gaudji G, Dlamini Z Int J Mol Sci. 2022; 23(22).

PMID: 36430229 PMC: 9693604. DOI: 10.3390/ijms232213750.


Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy.

Bouyahya A, El Allam A, Aboulaghras S, Bakrim S, El Menyiy N, Alshahrani M Cancers (Basel). 2022; 14(22).

PMID: 36428613 PMC: 9688668. DOI: 10.3390/cancers14225520.


The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An Study on a Novel Combination Strategy.

Zaryouh H, De Pauw I, Baysal H, Pauwels P, Peeters M, Vermorken J Front Oncol. 2021; 11:697967.

PMID: 34568028 PMC: 8462273. DOI: 10.3389/fonc.2021.697967.


Simultaneous Targeting Tumor Cells and Cancer-Associated Fibroblasts with a Paclitaxel-Hyaluronan Bioconjugate: In Vitro Evaluation in Non-Melanoma Skin Cancer.

Bellei B, Caputo S, Migliano E, Lopez G, Marcaccini V, Cota C Biomedicines. 2021; 9(6).

PMID: 34073987 PMC: 8225214. DOI: 10.3390/biomedicines9060597.